why choose us

First received: June 26, 2023

Clinical Trial: Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Obstructive Sleep Apnea

Study Type: INTERVENTIONAL


Official Title: Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

Brief Summary: This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG).Participants will receive ato-oxy for 6 months.Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine.Dosing of the study treatment will occur approximately 30 minutes prior to bedtime.Participants who withdraw from the study will not be replaced.Study participants will undergo eligibility…

Read more